{"id":"https://openalex.org/W4322769907","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-15","title":"Abstract P3-01-15: Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in African American (AA) patients with metastatic breast cancer (MBC)","display_name":"Abstract P3-01-15: Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in African American (AA) patients with metastatic breast cancer (MBC)","publication_year":2023,"publication_date":"2023-03-01","ids":{"openalex":"https://openalex.org/W4322769907","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-15"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs22-p3-01-15","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-15","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-01-15","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope Rugo","raw_affiliation_strings":["1University of California San Francisco, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of California San Francisco, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090463130","display_name":"Xianchen Liu","orcid":"https://orcid.org/0000-0003-0411-1050","observed_orcids":["https://orcid.org/0000-0003-0411-1050","https://orcid.org/0000-0002-4325-2545"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xianchen Liu","raw_affiliation_strings":["2Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Pfizer Inc","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023195809","display_name":"Benjamin C. Li","orcid":"https://orcid.org/0000-0002-1783-7013","observed_orcids":["https://orcid.org/0000-0002-1783-7013","https://orcid.org/0009-0005-1054-5228"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin Li","raw_affiliation_strings":["3Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Pfizer Inc","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042491180","display_name":"Lynn McRoy","orcid":"https://orcid.org/0000-0002-0986-5364","observed_orcids":["https://orcid.org/0000-0002-0986-5364"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lynn McRoy","raw_affiliation_strings":["4Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101442865","display_name":"Connie Chen","orcid":"https://orcid.org/0000-0001-5384-4707","observed_orcids":["https://orcid.org/0000-0001-5384-4707","https://orcid.org/0000-0002-5221-5711"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Connie Chen","raw_affiliation_strings":["5Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064168158","display_name":"Rachel M. Layman","orcid":"https://orcid.org/0000-0002-8663-0331","observed_orcids":["https://orcid.org/0000-0002-8663-0331"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel M. Layman","raw_affiliation_strings":["6The University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6The University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044108002","display_name":"Adam Brufsky","orcid":"https://orcid.org/0000-0001-8080-7960","observed_orcids":["https://orcid.org/0000-0001-8080-7960","https://orcid.org/0009-0006-2725-3579"]},"institutions":[{"id":"https://openalex.org/I4210098814","display_name":"UPMC Health System","ror":"https://ror.org/011htkb76","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814"]},{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam M. Brufsky","raw_affiliation_strings":["7UPMC Hillman Cancer Center, University of Pittsburgh Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7UPMC Hillman Cancer Center, University of Pittsburgh Medical Center","institution_ids":["https://openalex.org/I4210098814","https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"5_Supplement","first_page":"P3","last_page":"01"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/aromatase-inhibitors","display_name":"aromatase inhibitors","score":0.9470000267028809},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8659999966621399},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.9300000071525574},{"id":"https://openalex.org/keywords/african-american-patients","display_name":"African American patients","score":0.871999979019165},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.949999988079071},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.8080000281333923},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9200000166893005},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/racial-disparities","display_name":"racial disparities","score":0.6959999799728394},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.7910000085830688},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8299999833106995},{"id":"https://openalex.org/keywords/flatiron-health-database","display_name":"Flatiron Health database","score":0.6209999918937683},{"id":"https://openalex.org/keywords/electronic-health-records","display_name":"electronic health records","score":0.9150000214576721},{"id":"https://openalex.org/keywords/practice-patterns","display_name":"clinical practice patterns","score":0.4269999861717224}],"concepts":[{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.9118548631668091},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7972195148468018},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.682526171207428},{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.6054243445396423},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5619084239006042},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5609113574028015},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5383606553077698},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49246320128440857},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.47085636854171753},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.11184379458427429}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs22-p3-01-15","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p3-01-15","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-01-15","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"},{"score":0.4000000059604645,"display_name":"Reduced inequalities","id":"https://metadata.un.org/sdg/10"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4385190942","https://openalex.org/W2977725664","https://openalex.org/W4304190250","https://openalex.org/W4406074219","https://openalex.org/W4411287111","https://openalex.org/W4220923282","https://openalex.org/W4322769908","https://openalex.org/W2947775600","https://openalex.org/W4393068374","https://openalex.org/W7131290469"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Randomized":[2],"clinical":[3,14,57,79,108,233,261,464],"trials":[4],"and":[5,56,61,88,162,254,260,275,290,304,330,348,392,457,469],"a":[6,47,137],"growing":[7],"body":[8],"of":[9,16,92,140,170,195,207,221,249,257,413,455,492,511],"real-world":[10,83,442],"evidence":[11,421,454],"have":[12,323,332],"demonstrated":[13],"benefit":[15],"cyclin":[17],"dependent":[18],"kinase":[19],"4/6":[20],"inhibitors":[21,496],"(CDK4/6i)":[22],"in":[23,54,76,100,106,132,287,293,360,367,389,396,425,440,462,498],"combination":[24,426],"with":[25,103,148,255,273,280,312,317,427,431,437,446,503],"endocrine":[26,428],"therapy":[27,158],"for":[28,50,302,307,434,459],"HR+/HER2-":[29,51,104,149,438],"(MBC).":[30],"In":[31],"the":[32,133,145,205,208,246,265,340,441,512],"National":[33],"Comprehensive":[34],"Cancer":[35,517,528],"Network":[36],"(NCCN)":[37],"guidelines,":[38],"CDK4/6i":[39,77],"+":[40],"AI":[41,95,98,155,173,198,224,252,294,308,313,368,397,416,418],"or":[42,154,172,182,197,223,227,235],"Fulvestrant":[43],"is":[44,429],"recognized":[45],"as":[46,156,191,217],"preferred":[48],"regimen":[49],"MBC.":[52],"Disparities":[53],"survival":[55,86,90],"outcomes":[58,456,471],"between":[59,159],"AA":[60,70,101,142,435,460],"white":[62],"breast":[63,505],"cancer":[64,122,130,506],"patients":[65,71,102,131,143,289,362,369,391,398,436,461,502],"are":[66,449],"well":[67,74],"documented,":[68],"but":[69],"were":[72,166,202,212,242,271,278,319],"not":[73,356],"represented":[75],"randomized":[78],"trials.":[80],"We":[81,135],"compared":[82],"progression":[84],"free":[85],"(rwPFS)":[87],"overall":[89],"(OS)":[91],"palbociclib":[93,414,424,493],"plus":[94,415,494],"(PB+AI)":[96],"vs":[97,251,328,337,363,417],"alone":[99,419],"MBC":[105,150,326,439],"US":[107],"practices.":[109],"Methods:":[110],"The":[111],"Flatiron":[112,146],"Health":[113],"longitudinal":[114],"database":[115,147],"contains":[116],"electronic":[117],"health":[118],"records":[119],"from":[120,144,168,193,219],">280":[121],"clinics":[123],"representing":[124],">":[125],"2.4":[126],"million":[127],"actively":[128],"treated":[129,272,279,309,316],"US.":[134],"conducted":[136],"retrospective":[138],"analysis":[139,412],"270":[141,266],"who":[151],"started":[152,344],"PB+AI":[153,171,196,222,250,274,288,303,318,341,361,390],"first-line":[157,423],"February":[160],"2015":[161],"March":[163],"2020,":[164],"Patients":[165,201],"evaluated":[167,230],"start":[169,194,220],"to":[174,199,225,244,322,331,451],"September":[175],"30,":[176],"2020":[177],"(Data":[178],"cutoff":[179],"date),":[180],"death,":[181],"last":[183],"visit,":[184],"whichever":[185],"came":[186],"first.":[187],"OS":[188,354],"was":[189,215,284,299,355,381],"defined":[190,216],"months":[192,218,301,306,365,383,394],"death.":[200],"censored":[203],"at":[204,346],"end":[206],"study":[209],"if":[210],"they":[211],"living.":[213],"rwPFS":[214,380],"death":[226],"disease":[228],"progression,":[229],"based":[231],"on":[232],"assessment":[234],"radiographic":[236],"scan/tissue":[237],"biopsy.":[238],"Cox":[239],"proportional-hazards":[240],"models":[241],"used":[243],"estimate":[245],"relative":[247],"effectiveness":[248,433,470,491],"without":[253],"adjustment":[256],"baseline":[258],"demographics":[259],"characteristics.":[262],"Results:":[263],"Of":[264,339],"eligible":[267],"patients,":[268,295,314,342],"127":[269],"(47.0%)":[270],"143":[276],"(53.0%)":[277],"AI.":[281],"Median":[282,297,353,379],"age":[283],"64.0":[285],"years":[286,292],"68.0":[291],"respectively.":[296],"follow-up":[298],"24.0":[300],"18.2":[305],"patients.":[310],"Compared":[311],"those":[315],"more":[320],"likely":[321],"de":[324],"novo":[325],"(48.6%":[327],"30.8%)":[329],"\u22652":[333],"metastatic":[334,504],"sites":[335],"(41.7%":[336],"29.4%).":[338],"82.7%":[343],"PB":[345],"125mg/day":[347],"30.7%":[349],"experienced":[350],"dose":[351],"adjustment.":[352],"reached":[357],"(NR,":[358],"95%CI=(38.2-NR))":[359],"28.2":[364],"(95%CI=19.2-52.8)":[366],"(HR=0.46,":[370],"95%CI=0.31-0.68,":[371],"p":[372,401,407],"=<":[373],"0.001;":[374],"adjusted":[375],"HR=0.56,":[376],"95%CI=0.36-0.89,":[377],"p=0.013).":[378],"18.0":[382],"(95%CI":[384],"=":[385],"12.4":[386],"\u2013":[387],"26.7)":[388],"10.5":[393],"(95%CI=7.0-13.4)":[395],"(HR=0.63,":[399],"95%CI=0.44-0.88,":[400],"<":[402],"0.007;":[403],"Adjusted":[404],"HR=0.74,":[405],"95%CI=0.47-1.17,":[406],"=0.199).":[408],"Conclusions:":[409],"This":[410],"comparative":[411],"provides":[420],"that":[422],"associated":[430],"improved":[432],"setting.":[443],"Additonal":[444],"studies":[445],"larger":[447],"cohorts":[448],"needed":[450],"provide":[452],"additional":[453],"safety":[458],"routine":[463],"practice.":[465],"Table.":[466],"Patient":[467],"characteristics":[468],"Citation":[472],"Format:":[473],"Hope":[474],"Rugo,":[475],"Xianchen":[476],"Liu,":[477],"Benjamin":[478],"Li,":[479],"Lynn":[480],"McRoy,":[481],"Connie":[482],"Chen,":[483],"Rachel":[484],"M.":[485,488],"Layman,":[486],"Adam":[487],"Brufsky.":[489],"Real-world":[490],"aromatase":[495],"(AI)":[497],"African":[499],"American":[500],"(AA)":[501],"(MBC)":[507],"[abstract].":[508],"In:":[509],"Proceedings":[510],"2022":[513,519],"San":[514,522],"Antonio":[515],"Breast":[516],"Symposium;":[518],"Dec":[520],"6-10;":[521],"Antonio,":[523],"TX.":[524],"Philadelphia":[525],"(PA):":[526],"AACR;":[527],"Res":[529],"2023;83(5":[530],"Suppl):Abstract":[531],"nr":[532],"P3-01-15.":[533]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-03-03T00:00:00"}